B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Executive Director - Multiple Teams

Full-TimeUpdated on 10/23/2026Deadline 11/30/26
$263.5k - $319.3k+ Discretionary incentive cash + Stock opportunities
Expert
PhD
Cambridge, MA, USA+1 moreMore locations: Princeton, NJ, USA
RemotePreferred location is Cambridge, MA; remote arrangements considered case by case. Travel approximately 30%, domestic and international.
Biology & Biotech
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • PhD or equivalent advanced scientific training in immunology, inflammation biology, or a related discipline relevant to immune-mediated diseases.
  • At least 10 years of drug discovery and/or early development experience in the pharmaceutical or biotechnology industry, with deep hands-on expertise in immunology.
  • Strong understanding of immune-mediated disease biology across rheumatology, dermatology, gastroenterology, or related indications, and ability to assess external opportunities against BMS Research priorities.
  • Demonstrated ability to evaluate external scientific opportunities, including academic collaborations, biotech partnerships, platform technologies, and pre-IND or IND-stage assets.
  • Experience shaping external collaboration plans, including scientific objectives, work plans, milestones, governance structures, decision points, and success measures, and negotiating them with external partners.
  • Ability to represent Immunology external innovation and the Integrative Sciences mission to internal and external stakeholders.
  • Preferred: Track record of advancing therapeutic programs toward IND stage or beyond, with knowledge of scientific, translational, and operational requirements for decision-ready programs.
  • Preferred: Experience working across Research, Early Development, Business Development, Alliance Management, Legal, IP, Finance, Thematic Research Centers, and Therapeutic Area leadership, or equivalent cross-functional structures, to support disciplined opportunity triage and execution.
  • Preferred: Capability in building productive relationships, setting clear expectations, and keeping collaboration structures scientifically focused and operationally accountable.
  • Preferred: Understanding of financial, legal, contractual, and geographic considerations affecting external research collaborations, including non-U.S. partnerships.
Responsibilities
  • Communicate internal Immunology Research pipeline priorities to Integrative Sciences and align external search, evaluation, and triage activities with BMS Research principles and Enterprise Immunology Therapeutic Area strategy.
  • Lead the Immunology triage process within Integrative Sciences, ensuring disciplined, criteria-driven evaluation of external opportunities.
  • Identify, evaluate, and advance immunology opportunities—including academic collaborations, biotech partnerships, platform technologies, and pre-IND or IND-stage assets—that add to or complement the internal pipeline.
  • Form and lead cross-functional diligence teams evaluating collaboration opportunities, and provide expert scientific opinion during Business Development reviews and due diligence.
  • Partner with Search & Evaluation and Business Development transaction leads to advance prioritized opportunities on disciplined, accelerated timelines.
  • Work with Research Finance to ensure activities are aligned, captured, and approved within Research budgets.
  • Contribute to the design and execution of a blended external innovation strategy spanning corporate and academic collaborations.
  • Shape opportunities into practical collaboration plans with clear scientific objectives, work plans, milestones, governance structures, decision points, and success measures.
  • Advise on collaboration structures and contract development as scientific lead, working with Business Development, transaction leads, Legal, and IP.
  • Serve on joint governance committees and oversight bodies coordinating agreed research plans with academic and industry partners, keeping collaborations scientifically focused and operationally accountable.
  • Represent Integrative Sciences, as appropriate, to other BMS organizations, regulatory agencies, investors, partners, and the broader scientific community.
  • Communicate regularly with internal client and partner groups and their leadership about external research activities and progress.
  • Compose progress reports and decision documentation for senior management, and deliver presentations and briefings on scientific and organizational activities within the area of responsibility.
  • Model scientific leadership, collaborative behavior, and an enterprise mindset across Research and Integrative Sciences, consistent with BMS values.
Desired Qualifications
  • Track record of advancing therapeutic programs toward IND stage or beyond, with knowledge of scientific, translational, and operational requirements for decision-ready programs.
  • Experience working across Research, Early Development, Business Development, Alliance Management, Legal, IP, Finance, Thematic Research Centers, and Therapeutic Area leadership, or equivalent cross-functional structures, to support disciplined opportunity triage and execution.
  • Capability in building productive relationships, setting clear expectations, and keeping collaboration structures scientifically focused and operationally accountable.
  • Understanding of financial, legal, contractual, and geographic considerations affecting external research collaborations, including non-U.S. partnerships.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

8%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
Three defensive stocks to buy as AI selloff hits: BMY, Colgate and Gilead offer dividends

As investors question the costs and returns of the AI boom, some are turning to defensive stocks in healthcare and consumer goods. Three that pay quarterly dividends stand out: Bristol Myers Squibb, Colgate-Palmolive, and Gilead Sciences. Bristol Myers Squibb shares are up 14.3% this year, with a forward dividend yield of 4.3% and 18 straight years of increases. Second-quarter revenue reached $13 billion, with newer products making up nearly 60%. Colgate-Palmolive is up 20.2% this year and has raised its dividend for 64 years in a row. It reported second-quarter revenue of $5.36 billion. Gilead shares have gained 26%, against 13% for the S&P 500. Second-quarter HIV sales rose 12% to $5.7 billion.

BioPharma Watch
Oct 22nd, 2026
IHI and Bristol Myers Squibb launch National collaborative to expand access to cancer clinical trials.

IHI and Bristol Myers Squibb launch National collaborative to expand access to cancer clinical trials. Key Takeaway: The Institute for Healthcare Improvement and Bristol Myers Squibb launched a three-year initiative to enhance access to oncology clinical trials. The Cancer Collective Action Collaborative aims to address barriers faced by underrepresented populations, particularly in lung and breast cancer. The initiative will involve 24 teams working to improve patient engagement and trial participation. Price reaction · baseline $61.12 (2026-10-21 close) · hit pre-market · clean, no other BMY news in the window day 0 close · peak Market sentiment analysis. Positive factors. * Collaboration aims to improve access to cancer trials. * Focus on addressing disparities in trial participation. * Engagement with diverse healthcare stakeholders. * Evidence-based strategies for sustainable change. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 15 past catalysts Lead asset Phase 1 · Multiple Myeloma Three-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON-(BUSINESS WIRE)-The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This three-year effort will mobilize healthcare and community partners to drive meaningful, sustainable change in access to and participation in oncology clinical trials, with a particular emphasis on lung and breast cancer. "Removing barriers to clinical trials is both an imperative and an opportunity within our reach," said Shannon Stephens, MPH, IHI's Interim Vice President of Health Equity. "By valuing the lived expertise of patients alongside the clinical expertise of providers and taking a coordinated, collaborative approach, we can advance more equitable care and create sustainable change across the cancer care ecosystem." Building on the foundation established by the Rise to Health Coalition, the Collaborative will bring together 24 teams across the healthcare ecosystem to address clinical trial participation barriers among populations disproportionately affected by cancer. Through shared learning and coordinated action, teams will improve how health systems connect eligible patients to clinical trial opportunities; build reliable and inclusive pathways; strengthen patient and community engagement and trust; equip care teams and community partners; and leverage data to support continuous learning and improvement. "At BMS, we believe that every person should have the opportunity to benefit from our medicines and innovation, no matter who they are, where they live, or what they have," said Andrew Whitehead, Vice President, Head of Population Health at BMS. "The Cancer Collective Action Collaborative is an extension of our Population Health strategy, which shapes how we work to ensure access to care, including clinical trials that reflect the populations affected by disease." The challenge: advancing access and participation in oncology clinical trials. Cancer outcomes remain unequal across the United States. Black women are 38 percent more likely to die from breast cancer than White women, despite slightly lower incidence rates. Lung cancer mortality remains 14 percent higher among Black men than White men. Rural residents have significantly higher cancer incidence and mortality, such as 40 percent higher lung cancer risk, due to limited access to oncologists, fewer screening services, and longer travel distances for treatment. Patients also face unequal opportunities to participate in clinical trials. Approximately 80 percent of patients with cancer receive care from community oncologists, yet participation in clinical research remains uneven across care settings. Research has found that just 4.1 percent of patients at community cancer programs enroll in cancer treatment trials, compared with 21.6 percent at National Cancer Institute-designated comprehensive cancer centers. Racial, ethnic, and geographic differences in clinical trial participation further underscore the importance of addressing barriers associated with trial availability, recruitment processes, access to information, distance, and coordination across healthcare systems. "We cannot expect different outcomes if we continue to rely on the same approaches to clinical trial recruitment," said Dr. Megan Wanzo, Director of Global Patient Inclusion and Recruitment at BMS, who is leading the company's work on the Cancer Collective Action Collaborative. "Improving participation in oncology research requires us to examine how we make trials accessible, how we engage with communities, and how we equip health systems to connect patients to research opportunities. The opportunity before us is to move beyond identifying barriers to collectively changing the systems that sustain them." Through an in-person and virtual learning community, the Collaborative will bring together the following stakeholders to align efforts toward the Quintuple Aim for cancer care: - Health and healthcare organizations - Oncology practices - Community cancer centers - Community-based organizations - Patient advocacy organizations - People with lived experience Apply to join the Collaborative. IHI and BMS have completed the first phase of the initiative, co-designing the Collaborative using evidence-based improvement strategies to support effective collective action. With this foundation in place, IHI and BMS invite organizations to apply to join the Collaborative by November 30, 2026. Review the application details and apply here: https://go.ihi.org/4jyf3jT. For questions, contact [email protected]. About the Institute for Healthcare Improvement (IHI). The Institute for Healthcare Improvement (IHI) is a leading, globally recognized not-for-profit healthcare improvement organization that has been applying evidence-based quality improvement methods to meet current and future healthcare challenges for more than 30 years. IHI provides millions of people in healthcare with methods, tools, and resources to make care better, safer, and more equitable; convenes experts to enable knowledge sharing and peer-learning; and advises health systems and hospitals of all sizes in improving their systems and outcomes at scale. IHI's mission is to innovate and lead transformational improvement in health and healthcare worldwide. PRESS CONTACT: candice perodeau [email protected] 617-575-7723. Frequently asked questions. What is the purpose of the Cancer Collective Action Collaborative? The initiative aims to improve access to oncology clinical trials and address participation barriers. Who are the partners in this initiative? The initiative is a collaboration between the Institute for Healthcare Improvement and Bristol Myers Squibb. What cancers are primarily focused on in this initiative? The initiative focuses on lung and breast cancer. How can organizations join the Collaborative? Organizations can apply to join the Collaborative by November 30, 2026.

Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.